2016 to 2023 Saw Increase in NICU Admission Rate
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 19, 2025 -- From 2016 to 2023, there was an increase in the rate of neonatal intensive care unit (NICU) admissions, according to a March data brief published by the National Center for Health Statistics.
Joyce A. Martin, M.P.H., and Michelle J.K. Osterman, from the National Center for Health Statistics in Hyattsville, Maryland, used data from the National Vital Statistics System to describe trends in NICU admission in the United States overall and by maternal age, race, and Hispanic origin; gestational age and birth weight; and state of residence.
The researchers found that from 2016 to 2023, there was an increase in the percentage of infants admitted to a NICU in the United States from 8.7 to 9.8 percent; NICU rates increased for all maternal age groups. From 2016 to 2023, NICU rates increased for each race and Hispanic origin group, with the largest increases seen for infants born to American Indian and Alaska Native non-Hispanic, White non-Hispanic, and Black non-Hispanic mothers. Among all gestational age and birth-weight categories, the percentage of infants admitted to a NICU increased from 2016 to 2023. NICU rates increased in most states during the study period.
"Nearly one in 10 infants (9.8 percent) was admitted to a NICU in 2023, an increase of 13 percent from 2016," the authors write. "Increases from 2016 to 2023 were seen for each maternal age, race and Hispanic-origin group, gestational age and birth-weight category, and among most U.S. states.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-20 12:00
Read more

- Bladder Wall Thickness Reflects Severity of Bladder Inflammatory Conditions
- AAOS: Header Ban Linked to Decrease in Soccer-Linked Concussions in Children
- FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis
- AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
- Gynecological Problems Risk Heart, Brain Health
- Just One Hour of Screen Time Increases Risk of Nearsightedness
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions